SCHEMBL21160019

SCHEMBL21160019

Nc1ccc(-n2cc(-c3ccc4[nH]c5ccc(-c6cn(-c7ccc(N)cc7)nn6)cc5c4c3)nn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.48
MAPT P10636 1/20 0.47
SNCA P37840 1/20 0.47
CA1 P00915 7/20 0.46
CA2 P00918 7/20 0.46
CA5A P35218 7/20 0.46
CA5B Q9Y2D0 7/20 0.46
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
FLT3 P36888 3/20 0.44
P2RY14 Q15391 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PTGS2 P35354 7/20 0.41
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
SQSTM1 Q13501 1/20 0.41
GSK3B P49841 2/20 0.40
AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29531292 1.00 CDC7 (0.48) CDC7MAPTSNCACA1CA2
SCHEMBL21121923 0.83 PTGS2 (0.57) CDC7MAPTSNCACA1CA2
SCHEMBL29450944 0.83 PTGS2 (0.57) CDC7MAPTSNCACA1CA2
SCHEMBL21160021 0.82 P2RY14 (0.53) CDC7MAPTSNCAP2RY14
SCHEMBL29530631 0.82 P2RY14 (0.53) CDC7MAPTSNCAP2RY14
SCHEMBL23060802 0.80 HDAC3 (0.37) CDC7MAPTSNCACA1CA2
SCHEMBL21122002 0.79 HSD17B1 (0.63) MAPTSNCACA1CA2CA5A
SCHEMBL17473654 0.78 PIK3CA (0.56) CDC7CA1CA2CA5ACA5B
SCHEMBL21160017 0.75 MAPT (0.54) CDC7MAPTSNCAHSD17B1HSD17B2
SCHEMBL29531012 0.75 MAPT (0.54) CDC7MAPTSNCAHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS ROCHE SEQUENCING SOLUTIONS INC (US) 2025-03-06 US claimed
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds Roche Sequencing Solutions, Inc. (US) 2024-04-30 US claimed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP claimed
EP-3994262-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2022-05-11 EP claimed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US claimed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO claimed
WO-2025137293-A2 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. (US) 2025-06-26 WO disclosed
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds Roche Sequencing Solutions, Inc. (US) 2024-04-30 US disclosed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP disclosed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP disclosed
EP-3994262-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2022-05-11 EP disclosed
US-20220112548-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2022-04-14 US disclosed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US disclosed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
WO-2019135975-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT CDC7 918/4885MAPT 1455/4885SNCA 263/4885
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds POLN, POLB, POLRMT CDC7 918/4885MAPT 1455/4885SNCA 263/4885
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT CDC7 918/4885MAPT 1455/4885SNCA 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.